AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics, which spun out of Pfizer ...

Cerevel Therapeutics’ Parkinson’s ... reinforcing its blockbuster potential and no doubt delighting AbbVie, which has agreed to buy the company in an $8.7 billion deal. Tavapadon is just ...

In December last year, it announced the acquisition of neuroscience drugmaker Cerevel Therapeutics CERE. The deal is expected to close soon. AbbVie stock ... 1 Rank (Strong Buy) stocks here.

Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on AbbVie (ABBV – Research Report) and keeping the price target at ...

READ ALSO: 18 Best 52-Week Low Stocks to Buy Now According to Short ... In addition to strengthening its drug pipeline, AbbVie Inc (NYSE:ABBV) has acquired Cerevel therapeutics, significantly ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Cigna's pharma middleman, citing Humira's steep rise in cost over the years, will switch to its biosimilar competitors.

These patients previously had very limited options and ELAHERE changes that." - AbbVie Humira, which delivered global sales ...

AbbVie shares are nearing $200, likely facing resistance and a potential pullback to test support between $175 and $185.

CFRA maintains a "buy" rating on AbbVie with a price target of $195. The company also announced the acquisition of Cerevel Therapeutics recently for $8.7 billion, expanding its presence in the ...